Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
715 - Hi, I'm from the Arthritis Society. I have a company that is currently developing a product; in phase 2. They want to support/sponsor one of our tool in a field that is relevant to their upcoming indication. Content and material will be elaborate by the Society without any interference by the pharma company. Would that interfere with any regulation in Canada. If so, which one? Thanks Ken Gagnon kgagnon@arthritis.ca
-
The content and message of the piece that they are planning to sponsor/support would dictate the acceptability of the activity. If the content speaks to therapy, it should be reviewed to ensure that there is no competitive bias or off-label content. For example, if the piece were to discuss modulating a pathway for which there are no approved drugs with that specific mechanism of action, this would be deemed pre-NOC advertising and would not be acceptable. As such, we suggest that this type of content be reviewed as an opinion, to ensure that the content meets the regulations.
